ライフサイエンスコーパス: cancer cell line

1 ived from healthy human serum and a prostate cancer cell line.

2 ls of the GRPR-positive, PC-3 human prostate cancer cell line.

3 TRIP compared to the wild-type A2780 ovarian cancer cell line.

4 oinflammatory cytokines in the SUM159 breast cancer cell line.

5 rong anticancer activity against HT-29 colon cancer cell line.

6 nase activity from a single clonally derived cancer cell line.

7 s affected in an oxaliplatin resistant colon cancer cell line.

8 as 15.6 days versus 210 days, for the breast cancer cell line.

9 ity in the androgen-independent PC3 prostate cancer cell line.

10 for in vitro cytotoxicity against a panel of cancer cell lines.

11 tely apoptotic cell death in breast and lung cancer cell lines.

12 roliferation in both ovarian and endometrial cancer cell lines.

13 d-induced cytotoxicity against both prostate cancer cell lines.

14 ported sub-nanomolar potency against several cancer cell lines.

15 dependent cell migration and invasiveness in cancer cell lines.

16 d RNA interference and CRISPR screens in 290 cancer cell lines.

17 oxicity against normal cells and a series of cancer cell lines.

18 s a series of increasingly metastatic breast cancer cell lines.

19 xic and target-mediated selectivity on human cancer cell lines.

20 expression with THZ2 response, in a panel of cancer cell lines.

21 liferation, migration, and invasion in human cancer cell lines.

22 polyploid growth and multinucleation in lung cancer cell lines.

23 tivation in the presence of VISTA-expressing cancer cell lines.

24 panel, and GI(50) determinations for several cancer cell lines.

25 microvesicles (MVs) and source cells from 14 cancer cell lines.

26 e compounds may become selective for certain cancer cell lines.

27 RAF mutant cell lines than in wild-type KRAS cancer cell lines.

28 wed with picomolar potencies against certain cancer cell lines.

29 d from drug-sensitive but not drug-resistant cancer cell lines.

30 le siRNAs in a panel of NSCLC and colorectal cancer cell lines.

31 ective cytotoxicity of CXL146 toward the MDR cancer cell lines.

32 ndrial membrane dissipation by DOX, in human cancer cell lines.

33 les by the TCGA are mirrored in the prostate cancer cell lines.

34 identified by CRISPR-Cas9 screenings on 324 cancer cell lines.

35 oteoglycans in the adhesion and migration of cancer cell lines.

36 otein level and inhibited growth in multiple cancer cell lines.

37 tion of biomolecule carbonylation in various cancer cell lines.

38 t for chromosome alignment during mitosis in cancer cell lines.

39 , we built hundreds of models for the NCI-60 cancer cell lines.

40 cohorts and further confirmed in colorectal cancer cell lines.

41 ntration in MIA PaCa-2 and PANC-1 pancreatic cancer cell lines.

42 to single-agent anti-HER2 therapy in breast cancer cell lines.

43 ose-dependently reduced GRP78 protein in MDR cancer cell lines.

44 ic perturbations across pools of 100 or more cancer cell lines.

45 lery that inhibits growth of fungi and human cancer cell lines.

46 sentation complex in human and mouse ovarian cancer cell lines.

47 re recurrently heterogeneous within multiple cancer cell lines.

48 dependently derived LNCaP and LAPC4 prostate cancer cell lines.

49 e and three oxaliplatin-resistant colorectal cancer cell lines.

50 OV-3, and TYKNu) and one mouse (ID8) ovarian cancer cell lines.

51 s in six human mammary epithelial and breast cancer cell lines.

52 acetylation to compare non-cancer and breast cancer cell lines.

53 cond C4-2B reporter cell line, and six other cancer cell lines.

54 ith docetaxel resistance in nine endometrial cancer cell lines.

55 t (4T1) and prostate adenocarcinoma (TPSA23) cancer cell lines.

56 rials on the cell cycle of PANC-1 and AsPC-1 cancer cell lines.

57 ), and by assessing their effects on various cancer cell lines.

58 elevated PD-L1 levels in some lung and other cancer cell lines.

59 take of the probe into the cytosol in breast cancer cell lines.

60 n from the extracted protein mixtures of the cancer cell lines.

61 luation of their activity against five human cancer cell lines.

62 both the ERK and JNK pathways in a panel of cancer cell lines.

63 HER2 treatment in PIK3CA-mutant HER2+ breast cancer cell lines.

64 potent SHP2 inhibitor, in KYSE520 and MV4;11 cancer cell lines.

65 antiproliferative activity against multiple cancer cell lines.

66 n and drug testing in a panel of 20 prostate cancer cell lines.

67 or c-Src signaling, including in human lung cancer cell lines.

68 er cell lines, particularly against prostate cancer cell lines.

69 regulated by WDR5, across a diverse panel of cancer cell lines.

70 ntry and functions in several human prostate cancer cell lines.

71 amics and response to treatment of different cancer cell lines.

72 tate cancer), and one kind of EpCAM negative cancer cell line (293T kidney cancer).

73 3 ligase components across hundreds of human cancer cell lines(3-5), we identify CR8-a cyclin-depende

74 blished from a triple-negative murine breast cancer cell line (4T1), electric currents and potentials

75 This TRIP-resistant ovarian cancer cell line, A2780TR, was found to be 9 times less

76 rsely, overexpression of TRIB3 in a panel of cancer cell lines abolished the cytotoxic effects of rap

77 ion and use it to screen non-small-cell lung cancer cell lines against bioactive small molecules.

78 whole-genome sequencing of the SKBR3 breast cancer cell line and patient-derived tumor and normal or

79 In human breast cancer cell lines and 4T1 mouse mammary tumor cells, PD-

80 notecan (SN-38), on Trop-2 positive cervical cancer cell lines and a xenograft model.

81 rgeted therapy in a subset of HER2(+) breast cancer cell lines and allow cancer cells to proliferate

82 y and selectively inhibit the growth of some cancer cell lines and are proposed to target intracellul

83 liferation assays using patient-derived lung cancer cell lines and by analyzing downstream kinase sig

84 ne (EMD), in targeting c-Myc in several lung cancer cell lines and drug-resistant primary lung cancer

85 ype EGFR in an E3 ligase-dependent manner in cancer cell lines and effectively suppressed the growth

86 genesis and have been extensively studied in cancer cell lines and experimental models.

87 leotide synthesis differs profoundly between cancer cell lines and fresh human lung cancer tissues; t

88 FL3 response was diminished in colorectal cancer cell lines and human colorectal cancer tumoroids

89 of expression in human pancreatic and other cancer cell lines and human pancreatic cancer tissue mic

90 geAEOT on chromatin images of various breast cancer cell lines and human tissue samples, thereby link

91 olleagues performed an inhibitor screen with cancer cell lines and identified SQLE as an unique vulne

92 he landscape of heterogeneity within diverse cancer cell lines and identifies recurrent patterns of h

93 g with its promoter region in luminal breast cancer cell lines and indirectly through a distal estrog

94 rs show robust cytotoxic effects in multiple cancer cell lines and induce cell-cycle arrest and apopt

95 has promising activity against several human cancer cell lines and inhibits tumor cell migration, con

96 remarkable cytotoxicity in human pancreatic cancer cell lines and Kras(G12D); Trp52(R172H/+); Pdx-1

97 In studies of pancreatic cancer cell lines and mice, we found that ZIP4 increases

98 so be used as a method for authentication of cancer cell lines and not a replacement for the STR meth

99 la: see text] from tumor allografts of three cancer cell lines and observed a substantial reduction i

100 e measured paraspeckle parameters in several cancer cell lines and observed an increase in paraspeckl

101 n of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methyl

102 depleted or inhibited MAP3K19 in KRAS-mutant cancer cell lines and observed that this reduces viabili

103 own KDM3A in MiaPaCa-2 and S2-007 pancreatic cancer cell lines and overexpressed KDM3A in HPNE cells

104 epresent a measure of Ras dependency in both cancer cell lines and patient samples.

105 ne expression in large collections of breast cancer cell lines and patient tumors to identify transcr

106 Cancer cell lines and primary patient-derived malignant

107 Here, we found multiple BRCA1-mutant cancer cell lines and primary tumors with low levels of

108 expression of the two microRNAs in cervical cancer cell lines and primary tumors, indicating dysregu

109 Compound 1 was cytotoxic for both breast cancer cell lines and the majority of cells died by trea

110 e expression profiling of 165 pairs of human cancer cell lines and their Cas9-expressing derivatives

111 ss-of-function studies in several colorectal cancer cell lines and then tested in clinical samples.

112 -AzadC induced HEXIM1 expression in prostate cancer cell lines and triple negative breast cancers.

113 UBAP2 is highly expressed in both pancreatic cancer cell lines and tumor tissues of PDAC patients.

114 potent cytotoxins toward numerous pediatric cancer cell lines and were minimally toxic to nontumorig

115 In cancer cell lines and xenograft models, mRNA and protein

116 n kinase activity under hypoxia in different cancer cell-lines and how does hypoxia play a role in an

117 lates and validated with DNA from two breast cancer cell-lines and two patient tumour tissue samples

118 uman BC cell lines and one human endometrial cancer cell line, and results were compared with full ag

119 ntly enhanced AKT sensitivity in a subset of cancer cell lines, and a far richer array of PARP inhibi

120 ated in normal breast tissue and some breast cancer cell lines, and could be reversed by treatment wi

121 d the plasma membrane of breast and prostate cancer cell lines, and elicited reporter-gene expression

122 lon cancer specimens, human and murine colon cancer cell lines, and FXR transgenic mice, here we iden

123 observations, Akt3 up-regulates p53 in human cancer cell lines, and the expression of Akt3 positively

124 n, FOXA1 is hypermethylated in basal bladder cancer cell lines, and this is reversed by treatment wit

125 ct response to XL177A across a panel of ~500 cancer cell lines, and TP53 knockout rescues XL177A-medi

126 ld increased cytotoxicity against five human cancer cell lines, and up to 70-fold less toxicity in no

127 pin RNAs in AsPC-1 and MIA PaCa-2 pancreatic cancer cells lines, and in pancreatic cells from KPC and

128 Human cancer cell lines are frequently used as model systems t

129 Immortalized cancer cell lines are widely used in cancer research, fr

130 trong cytotoxicity toward various human lung cancer cell lines, as well as chemotherapeutic-resistant

131 monitoring tumor growth from a mouse breast cancer cell line (AT-3, Gpr81-negative) implanted in mam

132 mor activity against A549, PC-3, and HCT-116 cancer cell lines both in normoxia and hypoxia.

133 Six cancer cell lines (breast, prostate, and pancreas) and a

134 kinase inhibition in a MET-amplified gastric cancer cell line by a single, high exposure of the targe

135 tosis, was induced in seven of the 31 breast cancer cell lines by hypoxia.

136 down in primary cancer cells and pancreatic cancer cell lines by using small hairpin RNAs; cells wer

137 rall, (124)I-trametinib uptake in a panel of cancer cell lines can be blocked with cold trametinib, c

138 sources such as pan-cancer genomics data for cancer cell lines (CCLs) and tumors, and systematic phar

139 d molecular profiles of preclinical in-vitro cancer cell lines (CCLs) exist for many drugs, it is unc

140 nscriptomes, proteomes and drug responses of cancer cell lines (CCLs) is an emerging approach to unco

141 Our data indicate that cancer cell line collections are not representative of t

142 bits antiproliferative efficacy in the colon cancer cell line COLO 320DM in vitro.

143 ined to automatically identify four parental cancer cell line (COLO 704, EFO-21, EFO-27 and UKF-NB-3)

144 ns and surviving cells were also seen in the cancer cell lines COLO357 and HT29.

145 ectrometry (UPLC-MS/MS) on MDA-MB-231 breast cancer cell lines constructed with siRNA and CRISPR/Cas9

146 In several cancer cell lines, CRISPR-Cas9 knockout of RP genes did

147 affolds are reviewed, with their structures, cancer cell line cytotoxicity and in vivo antitumor acti

148 , which we classify as TMTs, in a pancreatic cancer cell line, Dartmouth-Hitchcock Pancreatic Cancer

149 In vivo, SHH interference in colon cancer cell lines decreased primary tumor growth and met

150 ed improved activity against mouse and human cancer cell lines defective in O-linked glycosylation.

151 ke B cells from NSCLC patients with two lung cancer cell lines demonstrate that the naive-like B cell

152 In vitro studies in human prostate cancer cell lines demonstrated that transient overexpres

153 hibition in both p53 wildtype and p53 mutant cancer cell lines, demonstrating that USP7 inhibitors ca

154 A large number of aggressive cancer cell lines display elevated levels of activated R

155 We found PTEN depletion in the prostate cancer cell line DU145 did not detectably impact express

156 ability, and promising cytotoxicity in three cancer cell lines (DU145, HeLa, A549).

157 The computationally derived RDIs across the Cancer Cell Line Encyclopedia (CCLE) cell lines show exc

158 wed proliferation and drug resistance in the Cancer Cell Line Encyclopedia (CCLE) dataset.

159 iling of cell line collections including the Cancer Cell Line Encyclopedia (CCLE) has focused primari

160 ssue Expression, The Cancer Genome Atlas and Cancer Cell Line Encyclopedia) and comprehensively analy

161 reast cancer through the TCGA breast cancer, Cancer Cell Line Encyclopedia, and CancerRx datasets.

162 rous oxidation state, in the Broad Institute Cancer Cell Line Encyclopedia.

163 ke experiments performed on the MCF-7 breast cancer cell line (ER-positive and HER(2)-negative) demon

164 hibitor-sensitive (HER2iS) and HER2iR breast cancer cell lines exhibit high sensitivity to THZ1, a ne

165 concept, we applied sci-Plex to screen three cancer cell lines exposed to 188 compounds.

166 e expression patterns of 31 different breast cancer cell lines exposed to hypoxic conditions.

167 ws selective and potent cytotoxicity against cancer cell lines expressing cytochrome P450 4F11.

168 ltiplexed single-cell RNA-seq to profile 198 cancer cell lines from 22 cancer types.

169 present in primary human cancer samples and cancer cell lines from different organs.

170 derived cell lines, we have established new cancer cell lines from four patients with gastrointestin

171 ough a systematic analysis of screen data in cancer cell lines generated by the Cancer Dependency Map

172 Additionally, various breast cancer cell lines growing in adherent, two-dimensional c

173 ments confirmed that CENPA promotes prostate cancer cell line growth.

174 RNA-seq analysis in human lung cancer cell line H1299 reveals that downregulated genes

175 Metastatic human pancreatic cancer cell lines had increased levels of PPP1R1B and lo

176 iproliferative effects in nonsmall cell lung cancer cell lines harboring SRC activation, thus providi

177 not mesenchymal-like, triple-negative breast cancer cell lines have increased epigen expression, seal

178 We performed Protect-seq on the human colon cancer cell line HCT-116 and observed overlap with previ

179 We found that the human colorectal cancer cell line, HCT-116, displayed reduced expression

180 Screening in the colorectal cancer cell lines HCT116 and SW620 validated the feasibi

181 spheroids formed from two established human cancer cell lines (HCT116 and CAL27) to single and combi

182 NA sequencing (RNA-seq) data from colorectal cancer cell lines (HCT116, RKO, and SW48) that were untr

183 uman Dermal Fibroblasts, HDF) and a cervical cancer cell line (HeLa), as a function of time and volta

184 e the uptake and excretion fluxes of a liver cancer cell line (HepG2) and use genome-scale metabolic

185 on renders aggressive triple-negative breast cancer cell lines highly responsive to chemotherapy.

186 Multifaceted characterizations of human cancer cell lines hold huge treasures for cancer researc

187 ha-glucosidase activities and ii) colorectal cancer cell line (HT29) growth was also studied.

188 SNHG7 regulates proliferation of breast cancer cell lines in a dose-dependent manner, and silenc

189 In this study, we cultured ovarian cancer cell lines in adherent and nonadherent conditions

190 HepG2 is one of the most widely used human cancer cell lines in biomedical research and one of the

191 etermining the metastatic potential of human cancer cell lines in mouse xenografts at scale.

192 t, is required for the viability of prostate cancer cell lines in vitro and for optimal xenograft tum

193 N' site) showing efficacy against a range of cancer cell lines in vitro.

194 values in the range of 0.4-50 muM in several cancer cell lines including murine metastatic breast can

195 inhibitory activities against various human cancer cell lines, including A549, Caco-2, and SF268 cel

196 overed a marked sensitivity of hematological cancer cell lines, including B-cell lymphomas, to the po

197 rmance was characterized using four prostate cancer cell lines, including PC-3, VCaP, DU-145, and LNC

198 these mutants in SW480 and HCT116 colorectal cancer cell lines increased their anchorage-independent

199 levels of HIF1A compared with nonmetastatic cancer cell lines; knockdown of PPP1R1B significantly re

200 Hence, newly established cancer cell lines may be useful models for further pharm

201 trated to test three kinds of EpCAM positive cancer cell lines (MCF-7 breast cancer, SW480 colon canc

202 ates, respectively, in the basal-like breast cancer cell line MCF10CA1a.

203 can type profile of proteins from the breast cancer cell line MCF7, and we quantitatively revealed th

204 cation of exosomes derived from three breast cancer cell lines (MCF7, MDA-MB-231 and SKBR3).

205 pho-proteomic and fluxomics data in a breast cancer cell-line (MCF7) across three different growth co

206 Conversely, in a breast cancer cell line MDA-MB-231 NMDAR blockade results in an

207 we demonstrate that in the metastatic breast cancer cell line MDA-MB-231, retromer regulates the matr

208 high ABCB1 expressing triple-negative breast cancer cell line (MDA-MB-231-luc) were treated with vary

209 C-3 (PC3) along with STAT3-proficient breast cancer cell lines (MDA-MB-231, SUM149) revealed that Sta

210 odulation of SASH1 levels in a panel of lung cancer cell lines mediated changes in cellular prolifera

211 ent potency to gemcitabine in the pancreatic cancer cell line MIA PaCa-2.

212 tigated using exosomes isolated from gastric cancer cell lines MKN-28, MKN-45, and SGC-7901.

213 uracil pattern upon drug treatments in human cancer cell line models derived from HCT116.

214 Here, we use cancer cell lines modified with CRISPR/Cas9 or stably-ex

215 he SWI/SNF complex, can sensitize colorectal cancer cell lines mutated in the other subunit, ARID1A,

216 new compounds were screened in the 60 human cancer cell lines of the NCI drug screen and showed pote

217 l as several Ras mutations in lung and colon cancer cell lines on fast 10 min gradient separations.

218 epithelial cells, human or mouse pancreatic cancer cell lines, or immune cells.

219 screening data on 265 compounds across 1074 cancer cell lines, our models identified 24 clinically e

220 ated cypate" and palmitic acid in two normal-cancer cell line pairs: lung cancer (A549)-normal (MRC9)

221 ntrations of the prodrugs against a panel of cancer cell lines, particularly against prostate cancer

222 performed studies with the human pancreatic cancer cell lines PATU-8988T, BxPC-3, PANC-1, and MiaPAC

223 Studies of the STAT3-deficient prostate cancer cell line PC-3 (PC3) along with STAT3-proficient

224 Pancreatic cancer cell lines (PD2560) were orthotopically injected

225 DynaFit revealed that cell fitness in cancer cell lines, primary cancer cells, and fibroblasts

226 A549, DU 145, HeLa, HCT 116, and MCF7 human cancer cell lines provide insights into the impact of st

227 ockdown of RAD51AP1 (RADP51AP1 KD) in breast cancer cell lines reduced tumor growth.

228 nse profile across genetically heterogeneous cancer cell lines relative to taxol or DDM; 3) reduced p

229 It was discovered that some lung cancer cell lines release surfactants only when placed i

230 antibody or CRISPR knockout of IL37 in lung cancer cell lines repolarized TAMs, resulting in recover

231 4a or hsa-miR-449a in HeLa and SiHa cervical cancer cell lines resulted in DNA damage response, S-pha

232 d phosphorylation of cortactin in pancreatic cancer cell lines, resulting in increased in F-actin at

233 fusion-dependent and ETS fusion-independent cancer cell lines revealed improved ETS fusion-independe

234 says against a representative panel of human cancer cell lines revealed that polyamines L1a and L5a d

235 ~210 clinically relevant proteins in >12,000 cancer cell line samples in response to ~170 drug compou

236 cally investigate this, we performed robotic cancer cell line screens and discovered a marked sensiti

237 using monotherapy data from high-throughput cancer cell line screens.

238 RT-qPCR experiment on seven genes in twelve cancer cell lines showed that the IntMTQ improved overal

239 d leukaemia cell line; and DU145, a prostate cancer cell line): silencing SP1 decreased AGAP2 protein

240 Here, using several human lung cancer cell lines, siRNA-mediated gene silencing, immuno

241 performed in uMUC1-expressing human ovarian cancer cell line SKOV3/Luc and control uMUC1(low) ES-2 c

242 ell lines were established using two ovarian cancer cell lines: SKOV3ip1 and HeyA8.

243 In lung cancer cell lines, SMURF2 overexpression increased EGFR

244 More and more clinical studies, cancer cell lines studies, CRISPR screening studies as w

245 ow sub-micromolar range among various tested cancer cell lines such as A2780 (0.23 muM), PC3 (0.48 mu

246 nd analysis of distinct melanoma and bladder cancer cell lines suggested differences in cancer cell-e

247 Depletion of exosomes from cancer cell line supernatant reduced nociceptive behavio

248 munized mice against challenge with a breast cancer cell line that expresses the same immunodominant

249 s, we developed and characterized an ovarian cancer cell line that is resistant to a previously studi

250 Finally, 45 inhibited proliferation of two cancer cell lines that are resistant to cancer drugs and

251 K5 knockout and overexpression in ER+ breast cancer cell lines that CK5 is important for tumorsphere

252 a strong antiproliferative effect on various cancer cell lines that could not be observed for BD fami

253 Prostate cancer cell lines that induce mixed osteoblastic lesions

254 e previously reported the creation of viable cancer cell lines that lacked detectable ORC1 or ORC2 pr

255 across a panel of genetically diverse mouse cancer cell lines that were cultured in the presence of

256 O) of SR-B1 in both human and mouse prostate cancer cell lines through CRISPR/Cas9-mediated genome ed

257 s transcriptionally silenced in basal breast cancer cell lines through histone deacetylation and CpG

258 Here, we edit the HCT116 colorectal cancer cell line to delete part of the hRpn13 Pru, produ

259 i-omics data generated from sensitivities of cancer cell lines to different therapeutic compounds.

260 On average, the sensitivity of human cancer cell lines to DNMDP is correlated with PDE3A expr

261 re we have expanded the characterizations of cancer cell lines to include genetic, RNA splicing, DNA

262 r, large-scale protein response resources of cancer cell lines to perturbations are not available, re

263 strategies, AR reconstructed fCNAs in seven cancer cell lines to reveal the complex architecture of

264 ell lung cancer (NSCLC) and SW620 colorectal cancer cell lines to SRA737.

265 ted deletion of DAB2IP in epithelial ovarian cancer cell lines upregulated expression of stemness-rel

266 Importantly, the murine cancer cell lines used in ICD studies often express vira

267 e with MCF-7, MDA-MB-231, and SK-BR-3 breast cancer cell lines using [Formula: see text] nuclear magn

268 e, CHK1, in a variety of non-small cell lung cancer cell lines using CRISPR-mediated genetic approach

269 findings indicate that proteomic analyses of cancer cell lines using different RPPA platforms can ide

270 cts, can now be systematically identified in cancer cell lines using high-throughput genetic perturba

271 an lung cancer tissues and immortalized lung cancer cell lines via indirect immunofluorescence and im

272 nregulation of Dab2 expression in pancreatic cancer cell lines was found to trigger induction of gene

273 in 2017, the proliferation of TNBC and other cancer cell lines was reported to be unaffected by genet

274 on, migration, and invasiveness of different cancer cell lines, we identified and characterized three

275 ient datasets, patient-derived organoids and cancer cell lines, we identify mSWI/SNF subunits that ar

276 Using genetic mouse models and human breast cancer cell lines, we show that deletion or depletion of

277 Using a panel of cancer cell lines, we show that rapalogs downregulate th

278 Using prostate cancer cell lines, we showed that INPP4B regulates AR tr

279 Pancreatic cancer cell lines were analyzed by gene-expression micro

280 Three different human pancreatic cancer cell lines were compared to normal pancreatic epi

281 Pancreatic cancer cell lines were engineered to knockdown PAF1 usin

282 rmal lung epithelial cell line and four lung cancer cell lines were treated with TGF-beta.

283 to exosomes isolated from all three gastric cancer cell lines when the mice were injected with MFC c

284 transition (EMT) using the Suit2 pancreatic cancer cell line, which has low endogenous ST6Gal-I and

285 the presence of a conditioned medium (CM) of cancer cell lines, which functioned as the tumor microen

286 overexpressed in SW480 and HCT116 colorectal cancer cell lines, which were analyzed by immunoblotting

287 eatic cancer MIAPaCa-2, and human colorectal cancer cell line WiDr.

288 sion is a mechanism for providing BRCA1-null cancer cell lines with a residual level of HR that is es

289 Interestingly, in cancer cell lines with amplified MYC expression, depleti

290 ncer, particularly because a large number of cancer cell lines with characteristic mesenchymal featur

291 asks for clustering and classification of 46 cancer cell lines with four different mRNA quantificatio

292 model, we not only predict drug responses in cancer cell lines with high accuracy but also identify f

293 135(full:mini) ratio) is increased in breast cancer cell lines with high CA.

294 erapy models have reconstituted immortalized cancer cell lines with immune components, often from per

295 ucidated its selective mechanism in four MDR cancer cell lines with one lead candidate (CXL146).

296 f AKT and HER2 was conducted in HER2+ breast cancer cell lines with or without PIK3CA mutations, whic

297 r cell lines without treatment and cases are cancer cell lines with treatment.

298 s been tested in vitro against MCF7 and A549 cancer cell lines with VA13 and MCF10a control cells.

299 Whereas, in treatment studies, controls are cancer cell lines without treatment and cases are cancer

300 nthesis, and inhibited tumor growth in human cancer cell line xenografts.